111 related articles for article (PubMed ID: 37844682)
1. Circulating glypican-4 is a new predictor of all-cause mortality in patients with heart failure.
Muendlein A; Heinzle C; Leiherer A; Brandtner EM; Geiger K; Gaenger S; Fraunberger P; Mader A; Saely CH; Drexel H
Clin Biochem; 2023 Nov; 121-122():110675. PubMed ID: 37844682
[TBL] [Abstract][Full Text] [Related]
2. Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease.
Muendlein A; Heinzle C; Leiherer A; Geiger K; Brandtner EM; Gaenger S; Fraunberger P; Saely CH; Drexel H
Int J Cardiol; 2022 Dec; 369():54-59. PubMed ID: 35944770
[TBL] [Abstract][Full Text] [Related]
3. Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients.
Muendlein A; Brandtner EM; Leiherer A; Geiger K; Heinzle C; Gaenger S; Fraunberger P; Mader A; Saely CH; Drexel H
Atherosclerosis; 2022 Mar; 345():33-38. PubMed ID: 35202959
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
[No Abstract] [Full Text] [Related]
5. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
[No Abstract] [Full Text] [Related]
6. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
7. Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer.
Muendlein A; Heinzle C; Brandtner EM; Leiherer A; Drexel H; Dechow T; Decker T
Oncol Res Treat; 2023; 46(4):151-156. PubMed ID: 36750040
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction.
Koller L; Kleber M; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer T; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
Eur J Heart Fail; 2014 Jul; 16(7):758-66. PubMed ID: 24806206
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction.
Kleber ME; Koller L; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
Circ Heart Fail; 2015 Jan; 8(1):25-32. PubMed ID: 25342739
[TBL] [Abstract][Full Text] [Related]
12. CT-IGFBP-4 as a novel prognostic biomarker in acute heart failure.
Konev AA; Kharitonov AV; Rozov FN; Altshuler EP; Serebryanaya DV; Lassus J; Harjola VP; Katrukha AG; Postnikov AB
ESC Heart Fail; 2020 Apr; 7(2):434-444. PubMed ID: 31967738
[TBL] [Abstract][Full Text] [Related]
13. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
[TBL] [Abstract][Full Text] [Related]
14. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction.
Winter MP; Kleber ME; Koller L; Sulzgruber P; Scharnagl H; Delgado G; Goliasch G; März W; Niessner A
Thromb Haemost; 2017 Feb; 117(3):471-478. PubMed ID: 27975104
[TBL] [Abstract][Full Text] [Related]
17. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
[TBL] [Abstract][Full Text] [Related]
18. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
Pocock SJ; Ferreira JP; Gregson J; Anker SD; Butler J; Filippatos G; Gollop ND; Iwata T; Brueckmann M; Januzzi JL; Voors AA; Zannad F; Packer M
Eur Heart J; 2021 Nov; 42(43):4455-4464. PubMed ID: 34423361
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure.
Liang L; Huang L; Zhao X; Zhao L; Tian P; Huang B; Feng J; Zhang J; Zhang Y
Clin Cardiol; 2022 Jul; 45(7):802-813. PubMed ID: 35621296
[TBL] [Abstract][Full Text] [Related]
20. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.
Welsh P; Kou L; Yu C; Anand I; van Veldhuisen DJ; Maggioni AP; Desai AS; Solomon SD; Pfeffer MA; Cheng S; Gullestad L; Aukrust P; Ueland T; Swedberg K; Young JB; Kattan MW; Sattar N; McMurray JJV
Eur J Heart Fail; 2018 Feb; 20(2):268-277. PubMed ID: 28960777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
